Increasing The Reach Of Cell And Gene Therapies

The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches. On the downstream side, we’ll highlight how a selective innovation approach focused on the weak points in unit operations combined with DOE optimization will ultimately result in a more time- and cost-effective process for cell and gene therapy manufacturers.